An overview of the diagnosis and treatment of erectile dysfunction
Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Qual...
Gespeichert in:
Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2006-01, Vol.66 (18), p.2339-2355 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2355 |
---|---|
container_issue | 18 |
container_start_page | 2339 |
container_title | Drugs (New York, N.Y.) |
container_volume | 66 |
creator | SIVALINGAM, Sivaprakasam HASHIM, Hashim SCHWAIBOLD, Hartwig |
description | Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference. |
doi_str_mv | 10.2165/00003495-200666180-00006 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68262732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200506909</galeid><sourcerecordid>A200506909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</originalsourceid><addsrcrecordid>eNptkV1PHCEUhomp0fXjL5hJTL0b5WOB4XLd2NrExBt7TRg4KM0MWJjV-O_LdFdNk3Iu4JzzvOTAi1BD8CUlgl_huthS8ZZiLIQgHW7nkthDC0Kkaoni-AtaYExoW_vyEB2V8mtOFVcH6JBI0hEmxQJdr2KTXiC_BHhtkm-mJ2hcMI8xlVAaE10zZTDTCHGa25DBTmGozFvxm1jPKZ6gfW-GAqe7_Rj9_HbzsL5t7-6__1iv7lq7JHhqu14QS4hjgA2VkljquVG0w4ab3lvv7NIJB4xh73rppWV9z7gUVlEBYDp2jC629z7n9HsDZdJjKBaGwURIm6JFRwWVjFbwfAs-mgF0iD5N2dgZ1qv6YRwLhVWlLv9D1XAwBpsi-PrOfwXdVmBzKiWD1885jCa_aYL1bIt-t0V_2PK3JKr0bDf6ph_BfQp3PlTg6w4wxZrBZxNtKJ9ct6S8DsH-AAFjk9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68262732</pqid></control><display><type>article</type><title>An overview of the diagnosis and treatment of erectile dysfunction</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>SIVALINGAM, Sivaprakasam ; HASHIM, Hashim ; SCHWAIBOLD, Hartwig</creator><creatorcontrib>SIVALINGAM, Sivaprakasam ; HASHIM, Hashim ; SCHWAIBOLD, Hartwig</creatorcontrib><description>Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.2165/00003495-200666180-00006</identifier><identifier>PMID: 17181376</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject>Androgens - therapeutic use ; Biological and medical sciences ; Constriction ; Cost of Illness ; Dopamine Agonists - therapeutic use ; Erectile Dysfunction - diagnosis ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - surgery ; Erectile Dysfunction - therapy ; Exercise Therapy ; Genital system. Reproduction ; Health Care Costs ; Hormone Replacement Therapy ; Humans ; Incidence ; Male ; Medical History Taking ; Medical sciences ; Pelvic Floor ; Pharmacology. Drug treatments ; Phosphodiesterase Inhibitors - therapeutic use ; Practice Guidelines as Topic ; Psychotherapy - methods ; Referral and Consultation ; Severity of Illness Index ; Surveys and Questionnaires ; Urologic Surgical Procedures, Male ; Vacuum ; Vasodilator Agents - therapeutic use</subject><ispartof>Drugs (New York, N.Y.), 2006-01, Vol.66 (18), p.2339-2355</ispartof><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2006 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</citedby><cites>FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18425690$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17181376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SIVALINGAM, Sivaprakasam</creatorcontrib><creatorcontrib>HASHIM, Hashim</creatorcontrib><creatorcontrib>SCHWAIBOLD, Hartwig</creatorcontrib><title>An overview of the diagnosis and treatment of erectile dysfunction</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><description>Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.</description><subject>Androgens - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Constriction</subject><subject>Cost of Illness</subject><subject>Dopamine Agonists - therapeutic use</subject><subject>Erectile Dysfunction - diagnosis</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - surgery</subject><subject>Erectile Dysfunction - therapy</subject><subject>Exercise Therapy</subject><subject>Genital system. Reproduction</subject><subject>Health Care Costs</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical History Taking</subject><subject>Medical sciences</subject><subject>Pelvic Floor</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Psychotherapy - methods</subject><subject>Referral and Consultation</subject><subject>Severity of Illness Index</subject><subject>Surveys and Questionnaires</subject><subject>Urologic Surgical Procedures, Male</subject><subject>Vacuum</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkV1PHCEUhomp0fXjL5hJTL0b5WOB4XLd2NrExBt7TRg4KM0MWJjV-O_LdFdNk3Iu4JzzvOTAi1BD8CUlgl_huthS8ZZiLIQgHW7nkthDC0Kkaoni-AtaYExoW_vyEB2V8mtOFVcH6JBI0hEmxQJdr2KTXiC_BHhtkm-mJ2hcMI8xlVAaE10zZTDTCHGa25DBTmGozFvxm1jPKZ6gfW-GAqe7_Rj9_HbzsL5t7-6__1iv7lq7JHhqu14QS4hjgA2VkljquVG0w4ab3lvv7NIJB4xh73rppWV9z7gUVlEBYDp2jC629z7n9HsDZdJjKBaGwURIm6JFRwWVjFbwfAs-mgF0iD5N2dgZ1qv6YRwLhVWlLv9D1XAwBpsi-PrOfwXdVmBzKiWD1885jCa_aYL1bIt-t0V_2PK3JKr0bDf6ph_BfQp3PlTg6w4wxZrBZxNtKJ9ct6S8DsH-AAFjk9Q</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>SIVALINGAM, Sivaprakasam</creator><creator>HASHIM, Hashim</creator><creator>SCHWAIBOLD, Hartwig</creator><general>Adis International</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>An overview of the diagnosis and treatment of erectile dysfunction</title><author>SIVALINGAM, Sivaprakasam ; HASHIM, Hashim ; SCHWAIBOLD, Hartwig</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Androgens - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Constriction</topic><topic>Cost of Illness</topic><topic>Dopamine Agonists - therapeutic use</topic><topic>Erectile Dysfunction - diagnosis</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - surgery</topic><topic>Erectile Dysfunction - therapy</topic><topic>Exercise Therapy</topic><topic>Genital system. Reproduction</topic><topic>Health Care Costs</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical History Taking</topic><topic>Medical sciences</topic><topic>Pelvic Floor</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Psychotherapy - methods</topic><topic>Referral and Consultation</topic><topic>Severity of Illness Index</topic><topic>Surveys and Questionnaires</topic><topic>Urologic Surgical Procedures, Male</topic><topic>Vacuum</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SIVALINGAM, Sivaprakasam</creatorcontrib><creatorcontrib>HASHIM, Hashim</creatorcontrib><creatorcontrib>SCHWAIBOLD, Hartwig</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SIVALINGAM, Sivaprakasam</au><au>HASHIM, Hashim</au><au>SCHWAIBOLD, Hartwig</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An overview of the diagnosis and treatment of erectile dysfunction</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><addtitle>Drugs</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>66</volume><issue>18</issue><spage>2339</spage><epage>2355</epage><pages>2339-2355</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><coden>DRUGAY</coden><abstract>Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>17181376</pmid><doi>10.2165/00003495-200666180-00006</doi><tpages>17</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0012-6667 |
ispartof | Drugs (New York, N.Y.), 2006-01, Vol.66 (18), p.2339-2355 |
issn | 0012-6667 1179-1950 |
language | eng |
recordid | cdi_proquest_miscellaneous_68262732 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Androgens - therapeutic use Biological and medical sciences Constriction Cost of Illness Dopamine Agonists - therapeutic use Erectile Dysfunction - diagnosis Erectile Dysfunction - drug therapy Erectile Dysfunction - surgery Erectile Dysfunction - therapy Exercise Therapy Genital system. Reproduction Health Care Costs Hormone Replacement Therapy Humans Incidence Male Medical History Taking Medical sciences Pelvic Floor Pharmacology. Drug treatments Phosphodiesterase Inhibitors - therapeutic use Practice Guidelines as Topic Psychotherapy - methods Referral and Consultation Severity of Illness Index Surveys and Questionnaires Urologic Surgical Procedures, Male Vacuum Vasodilator Agents - therapeutic use |
title | An overview of the diagnosis and treatment of erectile dysfunction |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A36%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20overview%20of%20the%20diagnosis%20and%20treatment%20of%20erectile%20dysfunction&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=SIVALINGAM,%20Sivaprakasam&rft.date=2006-01-01&rft.volume=66&rft.issue=18&rft.spage=2339&rft.epage=2355&rft.pages=2339-2355&rft.issn=0012-6667&rft.eissn=1179-1950&rft.coden=DRUGAY&rft_id=info:doi/10.2165/00003495-200666180-00006&rft_dat=%3Cgale_proqu%3EA200506909%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68262732&rft_id=info:pmid/17181376&rft_galeid=A200506909&rfr_iscdi=true |